Polycythemia Vera: A Comprehensive Review and Clinical Recommendations

Tefferi, Ayalew
February 2003
Mayo Clinic Proceedings;Feb2003, Vol. 78 Issue 2, p174
Academic Journal
Presents a review of polycythemia vera (PV) and provides clinical recommendations. Use of phlebotomy as standard treatment of PV; Contraindications; Utility of selective serotonin receptor antagonists for treating PV-associated pruritus; Proposal of a modern algorithm to formulate a working diagnosis for PV; Recommendations for patient management.


Related Articles

  • Cardiovascular events and intensity of treatment in polycythemia vera. Mead, Adam // Current Medical Literature: Leukemia & Lymphoma;2013, Vol. 21 Issue 1, p33 

    The article reviews a study on whether to maintain the hematocrit at <0.45 with a combination of venesection and/or cytoreductive treatment in treating patients with polycythemia vera (PV) in 2013. Patients with PV were reportedly randomized to a low hematocrit target arm and those with a high...

  • An unusual case of toe ulceration. Lankipalli, Ramarao; Konkle, Barbara; Mohler III, Emile R. // Vascular Medicine;2006, Vol. 11 Issue 1, p35 

    We describe an unusual presentation of toe ulceration in a 39-year-old otherwise healthy man. The left fifth toe was painful for several months with ulceration at the tip. The other toes appeared cyanotic and discolored. Foot pulses were normal. Laboratory testing revealed the platelet count at...

  • Polycythemia Vera.  // American Family Physician;5/1/2004, Vol. 69 Issue 9, p2146 

    Provides information on polycythemia vera (PV). Relation of PV with bone marrow problem; Importance of blood test in knowing the symptoms of PV; Use of phlebotomy to treat PV.

  • Polycythemia Vera. Stuart, Brian J.; Viera, Anthony J. // American Family Physician;5/1/2004, Vol. 69 Issue 9, p2139 

    Polycythemia vera is a chronic myeloproliferative disorder characterized by increased red blood cell mass. The resultant hyperviscosity of the blood predisposes such patients to thrombosis. Polycythemia vera should be suspected in patients with elevated hemoglobin or hematocrit levels,...

  • Use and risks of phosphorus-32 in the treatment of polycythaemia vera. Parmentier, Claude // European Journal of Nuclear Medicine & Molecular Imaging;2003, Vol. 30 Issue 10, p1413 

    The risk of development of cancer, and more specifically acute leukaemia, after use of phosphorus-32 in patients with polycythaemia vera has been recognised for approximately 40 years. As a consequence of this risk, the indications for, and contraindications to,32 P are unclear in the...

  • Polycythemia vera and pregnancy: experience of four pregnancies in a single patient. Aggarwal, Neelam; Chopra, Seema; Suri, Vanita; Sikka, Pooja; Goundan, Aditi; Malhotra, Pankaj // Archives of Gynecology & Obstetrics;Feb2011, Vol. 283 Issue 2, p393 

    Introduction: The association of polycythemia vera (PV) and pregnancy is rare. The estimated incidence ranges from 0.04 per 100,000 in women aged 20-34 years to 0.25 per 100,000 in those aged 35-39 years. The management of pregnant patient with PV may be problematic; less than 50 pregnancies...

  • Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. Merx, Kirsten; Fabarius, Alice; Erben, Philipp; Griesshammer, Martin; Reiter, Andreas; Hofmann, Wolf-Karsten; Hehlmann, Rüdiger; Hochhaus, Andreas; Lengfelder, Eva // Annals of Hematology;Jul2013, Vol. 92 Issue 7, p907 

    The antiproliferative effects of the tyrosine kinase inhibitor imatinib mesylate were reported in single cases with polycythemia vera (PV). We, therefore, conducted a clinical phase II study to assess the rate and quality of response in patients with PV. Thirty-one patients, with a median age of...

  • Aconitase Regulation of Erythropoiesis Correlates with a Novel Licensing Function in Erythropoietin-Induced ERK Signaling. Talbot, Anne-Laure; Bullock, Grant C.; Delehanty, Lorrie L.; Sattler, Martin; Zhao, Zhizhuang Joe; Goldfarb, Adam N. // PLoS ONE;2011, Vol. 6 Issue 8, p1 

    Background: Erythroid development requires the action of erythropoietin (EPO) on committed progenitors to match red cell output to demand. In this process, iron acts as a critical cofactor, with iron deficiency blunting EPO-responsiveness of erythroid progenitors. Aconitase enzymes have recently...

  • Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Finazzi, G.; Barbui, T. // Leukemia (08876924);Dec2008 Supplement, Vol. 22, pP97 

    Major causes of morbidity and mortality in polycythemia vera (PV) and essential thrombocythemia (ET) are represented by thrombosis and bleeding, progression to myelofibrosis and transformation to acute leukemia. Myelosuppressive therapy, preferentially with hydroxyurea, can reduce the rate of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics